BMS-189453

BMS-189453

Stock Code: 3574531
Manufacturer Part No: SML1149-5MG
Order Now for 7 day delivery
£144.86 (exc VAT) per 5MG
Quantity: - +

Biochem/physiol Actions


BMS-189453 specifically has sufficient bioavailability in rats and monkeys. BMS-189453 only binds to ?, ?, and ? retinoid receptors but its activation is unknown. BMS-189453 is found to inhibit the action of collagenase-3 (MMP-13) which catalyses cartilage matrix degradation. Thus, it serves to treat rheumatoid arthritis.


BMS-189453 is a potent RARβ agonist that acts as an antagonist against RARα and RARγ. BMS-189453 induces RARβ reporter gene expression at sub nanomolar levels, and is 30 fold more potent than all-trans retinoic acid for inducing TGFβ activity in normal breast cells. The compound BMS-189453 does not transactivate RARα or γ transcriptional activity, but binding to those family members induces a strong transrepression of phorbol ester-induced AP-1 activity (IC50 = 0.1 nM in HeLa and MCSF-7). BMS-189453 significantly increases the efficiency of cardiac differentiation of hESCs.


Features and Benefits


This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.


Packaging


5, 25 mg in glass bottle

Colourwhite to beige
Quality Level100
InChI keyVUODRPPTYLBGFM-CMDGGOBGSA-N
InChI1S/C27H24O2/c1-27(2)17-16-23(21-6-4-3-5-7-21)24-18-20(12-15-25(24)27)9-8-19-10-13-22(14-11-19)26(28)29/h3-16,18H,17H2,1-2H3,(H,28,29)/b9-8+
ManufacturerSIGMA-ALDRICH
SolubilityDMSO: 10 mg/mL, clear
Formpowder
Assay≥98% (HPLC)

There are no downloads for this product.